<DOC>
	<DOCNO>NCT00022048</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , bevacizumab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill deliver cancer-killing substance . PURPOSE : This phase I/II trial see bevacizumab work treat patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Bevacizumab Treating Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Determine hematologic response , include change hemoglobin level , neutrophil count , platelet count , percentage bone marrow blast , patient myelodysplastic syndrome treat bevacizumab . - Determine toxic effect regimen patient . - Determine tolerance patient treat regimen . - Determine bone marrow cytogenetic response patient treat regimen . - Determine bone marrow microvessel density patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord International Prognostic Scoring System risk status ( low ( low intermediate-1 ) v high ( intermediate-2 high ) ) . Patients receive bevacizumab IV 30-90 minute . Treatment repeat every 2 week 4-6 month absence disease progression unacceptable toxicity . Patients follow week 1 , 3 , 5 , 7 , 9 . PROJECTED ACCRUAL : A total 16-25 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm myelodysplastic syndrome ( MDS ) Refractory anemia ( RA ) RA excess blast ( RAEB ) RAEB transformation RA ring sideroblast Nonproliferative chronic myelomonocytic leukemia ( WBC less 12,000/mm^3 ) At least 1 follow cytopenia : Untransfused hemoglobin great 10.0 g/dL and/or red cell transfusion dependent Absolute neutrophil count great 1,800/mm^3 ( neutropenia ) Platelet count great 100,000/mm^3 ( thrombocytopenia ) No secondary MDS No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Karnofsky 60100 % Life expectancy : More 4 month Hematopoietic : See Disease Characteristics Platelet count least 20,000/mm^3 No hemorrhagic illness within past 3 week No hemolysis No iron deficiency No active blood loss Hepatic : AST ALT great 2.5 time upper limit normal ( ULN ) Bilirubin great 2.0 mg/dL INR le 2.0 PTT less 1.5 time ULN Renal : Creatinine great 2.0 mg/dL No renal dysfunction require dialysis within past 6 month No nephrotic syndrome within past 6 month Cardiovascular : No myocardial infraction within past 6 month No severe unstable angina within past 6 month No severe peripheral vascular disease ( ischemic rest pain , nonhealing wound ulcer , tissue loss ) within past 6 month No uncontrolled hypertension within past 6 month No transient ischemic attack within past 6 month No cerebrovascular accident within past 6 month No deep venous arterial thrombosis No coronary artery disease No symptomatic congestive heart failure ( New York Heart Association class IIIV heart disease ) No cardiac arrhythmia No vascular illness within past 3 week Pulmonary : No pulmonary embolism Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active malignancy except localize squamous cell basal cell skin cancer Prior cure malignancy allow No trauma within past 3 week No significant inflammatory disease within past 3 week No serious nonhealing wound , ulcer , bone fracture No hypersensitivity Chinese hamster ovary cell product recombinant human humanize antibodies No active severe disease No infection No psychiatric illness social situation would preclude study compliance HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : No prior allogeneic bone marrow transplantation At least 30 day since prior biologic response modifier At least 30 day since prior hematopoietic growth factor At least 30 day since prior thalidomide No concurrent thalidomide No concurrent biologic response modifiers No concurrent hematopoietic growth factor ( include epoetin alfa ) Concurrent filgrastim ( GCSF ) febrile neutropenia allow Concurrent transfusion allow Chemotherapy : At least 30 day since prior chemotherapy No concurrent chemotherapy Endocrine therapy : No concurrent corticosteroid therapy ( 10 mg/day prednisone equivalent steroid dose ) except premedication transfusion Radiotherapy : At least 30 day since prior radiotherapy No concurrent radiotherapy Surgery : At least 3 week since prior surgery ( include biopsy visceral organ ) Other : At least 10 day since prior anticoagulant No concurrent cytotoxic agents No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2004</verification_date>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
</DOC>